¹¤³ÌÏîÄ¿×ÊÁÏÔ± ÃæÒé ÊÕ²Ø ÉêÇëְλ
Ê×Ò³ > Ì©ÖÝÕÐÆ¸ > ¹¤³ÌÏîÄ¿×ÊÁÏÔ±

¹¤³ÌÏîÄ¿×ÊÁÏÔ±

Ì©ÖÝÂõ²©Ì«¿ÆÒ©ÒµÓÐÏÞ¹«Ë¾

Ë¢ÐÂÓÚ£º2015-07-28±»ä¯ÀÀ£º980´Î

ÃæÒé

²»ÏÞ / ¸ßÖÐ / ÐÔ±ð²»ÏÞ / ÃæÒé / ²»ÏÞµ½¸Ú

½­ËÕ-Ì©ÖÝ £¨Ì©ÖÝÒ½Ò©¸ßм¼Êõ²úÒµÔ°¿Ú̩·Î÷²à½¼Ò·¶«²àG79´± £© Éϰà·Ïß²éѯ

ÕÐÆ¸ÃæÒé

³Â
ְλ·¢²¼ÈË£º³ÂÏÈÉú

139****6549,052****713092 ÏÔʾºÅÂë

(ÁªÏµÊ±Çë˵Ã÷ÊÇÔÚÐÂÌ©ÖÝÈ˲ÅÍøÉÏ¿´µ½µÄ)

´òµç»°Ç°ÏÈͶ¸ö¼òÀú£¬»ñµÃÃæÊԵijɹ¦ÂÊÔö¼Ó30%

Ì©ÖÝÈ˲ÅÍøÌáʾ£ºÌ©ÖÝÂõ²©Ì«¿ÆÒ©ÒµÓÐÏÞ¹«Ë¾ÎÞȨÊÕÈ¡ÈκηÑÓã¬Çë¹ã´óÇóÖ°Õß¼ÓÇ¿×ÔÎÒ±£»¤Òâʶ£¬°´ÀͶ¯·¨¹æ±£»¤×ÔÉíÈ¨Òæ£¬¾¯ÌèÐé¼ÙÕÐÆ¸,±ÜÃâÉϵ±ÊÜÆ­£¡ ¾Ù±¨´Ëְλ
ְλÃèÊö

¸ÚλְÔð£ºÔÚ¹¤³ÌÏîÄ¿ÆÚ¼ä¸ºÔ𹤳Ì×ÊÁϵÄÕûÀíÎļþµÄÊÕ·¢µÈ£»

¹¤³Ì½áÊøºóµÄÔËÐн׶Î×÷Ϊ¹¤³Ì²¿µÄÉ豸¹ÜÀíÔ±£¬¸ºÔðÉ豸¹ÜÀí×ÊÁϱ¸Æ·Åä¼þ¹ÜÀíµÈ¡£
1.
¸ºÔðÏîÄ¿µÄ¸÷ÖÖͼֽÎļþ×ÊÁϵĶÔÍâ·¢·Å£¬²¢µÇ¼Ç¡£
2.
¸ºÔðËùÓÐÊ©¹¤µ¥Î»¼àÀíµ¥Î»À´ÎĵĽÓÊܵǼDZ£¹Ü¡£
3.
¶Ô¹¤³Ì×ÊÁϽøÐпÆÑ§¹æ·¶µÄ±àºÅµÇ¼Ç±£¹Ü¡£
4.
¸ºÔð¸÷ÖÖͼֽ×ÊÁϵĽèÔĸ´Ó¡£
¬½èÔĸ´Ó¡¾ùÐèÂÄÐÐÉóÅúÊÖÐø²¢µÇ¼Ç¡£

¹«Ë¾¼ò½é
Ì©ÖÝÂõ²©Ì«¿ÆÒ©ÒµÓÐÏÞ¹«Ë¾ÓÚ2015ÄêÈëפ̩ÖÝÊÐÖйúÒ½Ò©³Ç£¬×¢²á×ʱ¾2000ÍòÃÀÔª¡£¹«Ë¾Ö÷Òª´Óʵ¥¿¹Ò©ÎïÉú²ú£¬Í¶×Ê×ܶî2ÒÚÃÀÔª£¬Ä⽨³§·¿Ãæ»ý3ÍòÓàÆ½·½£¬½¨Éè·ûºÏGMP±ê×¼µÄ¹ú¼ÊÏȽøµÄ¿¹ÌåÒ©ÎïÖÆ±¸Ìåϵ£¬ÒÔÆÚ´òÔì¹úÄÚ¿¹ÌåÒ©ÎïÉú²ú¸ßµØ¡£Âõ²©Ì«¿ÆÒ©ÒµÓÉÉϺ£ÕŽ­ÉúÎï¼¼ÊõÓÐÏÞ¹«Ë¾£¨¿¹ÌåÒ©ÎïÓë°ÐÏòÖÎÁƹú¼ÒÖØµãʵÑéÊÒ£©¿¹ÌåÑз¢ÍŶÓÌṩһվʽƽ̨·þÎñ£¬ÖÂÁ¦ÓÚʵÏÖһϵÁÐÖØÁ¿¼¶¹ú¼Ò´´Ð¿¹ÌåÒ©ÎïµÄ²úÒµ»¯¡£ÏÖÓÐÆ·ÖÖ£ºÖÎÁƽáÖ±³¦°©µÄÖØ×鿹EGFRÈËÊóǶºÏµ¥¿Ë¡¿¹Ì壬ÖÎÁÆÒøÐ¼²¡µÄÖØ×éÈËLFA3-¿¹ÌåÈںϵ°°×µÈ¡£TaizhouMabtechPharmaceuticalCo.,Ltd.joinedtheChinaMedicalCity(CMC)in2015withregisteredcapitalofUSD20million,expandinganationalhighlandformonoclonalantibodymedicinemanufacturingbyestablishinginternationallyadvancedantibodymedicinemanufacturesystemwithadoptedcGMPstandards,withatotalinvestmentofUSD200million.Supportedbytheone-stopplatformfortherapeuticmAbmedicinedevelopmentprovidedbyZJ-BioR&DTeam(StateKeyLaboratoryofAntibodyMedicineandTargetedTherapy),TaizhouMabtechPharmaceuticsCo.,Ltdisdedicatedtoindustrializationofaseriesof¡°blockbuster¡±innovativeantibodydrugs.Existingvarieties:recombinantanti-EGFRhuman/mouse-chimericmonoclonalantibodyforthetreatmentofcolorectalcancer,recombinanthumanLFA3-antibodyfusionproteinforthetreatmentofpsoriasis,etal.
¸Ã¹«Ë¾µÄÆäTAְλ
Ì©ÖÝÂõ²©Ì«¿ÆÒ©ÒµÓÐÏÞ¹«Ë¾
  • ÖÆÔìÒµ
  • ÍâÉÌͶ×ÊÆóÒµ
  • ½­ËÕ-Ì©ÖÝ
  • 100-1000ÈË
0%¼òÀú·´À¡ÂÊ
0ƽ¾ù»Ø¸´Ê±³¤
0¸öÕÐÆ¸Ö°Î»
ְλÃû³Æ£º¹¤³ÌÏîÄ¿×ÊÁÏÔ±
¹«Ë¾Ãû³Æ£º Ì©ÖÝÂõ²©Ì«¿ÆÒ©ÒµÓÐÏÞ¹«Ë¾
 
ÏàËÆÖ°Î»
  • ×ÊÁÏÔ±
    ÃæÒé Ì©ÖÝ-Ì©ÐË
    Ì©ÖÝÁªÌ©¹Ì·Ï´¦ÖÃÓÐÏÞ¹«Ë¾
  • °²×°¼¼ÊõÔ±
    ÃæÒé Ì©ÖÝ-Ì©ÐË
    ½­ËÕ½ðï³ÉÐË»·±£¿Æ¼¼ÓÐÏÞ¹«Ë¾
  • ¹¤³Ì×ÊÁÏÔ±
    6ǧ-8ǧ/Ô ̩ÖÝ-Ì©ÐË
    ½­ËÕ·ïÃùÉÌÒµ¹ÜÀíÓÐÏÞ¹«Ë¾
  • ×ÊÁÏÔ±
    ÃæÒé Ì©ÖÝ-Ì©ÐË
    ½­ËÕ²©Ì©ºë³É½¨É蹤³ÌÓÐÏÞ¹«Ë¾